Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors - NCT05194735

Phase I: To evaluate safety and tolerance of the cell transfer using common terminology criteria for adverse events (CTCAE v5.0), Phase II: To determine the objective response rate (ORR) (using RECIST v1.1 criteria) of subjects with solid cancers who receive autologous TCR-T cells, Phase II: To evaluate the safety and tolerance of the TCR-T cell infusion using standard CTCAE 5.0., (and 7 more...)